Journal: World Journal of Gastroenterology

Article Title: Evaluation of a 3,5-diethoxycarbonyl-1,4-dihydrocollidine diet-induced mouse model in a comparative experimental study of portal hypertension

doi: 10.3748/wjg.v32.i9.114207

Figure Lengend Snippet: The 3,5-diethoxycarbonyl-1,4-dihydrocollidine diet mouse model (4 weeks) exhibited moderate biliary fibrosis in the portal vein region. A: Hematoxylin-eosin, Masson, and Sirius red staining of mouse livers; B-G: Statistical analysis of Masson and Sirius red staining results; H: Immunohistochemistry staining for collagen-1, α-smooth muscle actin (SMA), and desmin in mouse livers; I-Q: Statistical analysis of collagen-1, α-SMA, and desmin staining results. Sample sizes ( n ): 8:8 (normal chow diet vs 3,5-diethoxycarbonyl-1,4-dihydrocollidine), 8:7 (sham vs bile duct ligation), and 8:7:8 (oil vs 8-week carbon tetrachloride vs 12-week carbon tetrachloride). a P < 0.05. b P < 0.01. c P < 0.001. NS: No significant; NCD: Normal chow diet; DDC: 3,5-diethoxycarbonyl-1,4-dihydrocollidine; BDL: Bile duct ligation; CCl 4 : Carbon tetrachloride; HE: Hematoxylin-eosin; COL1: Collagen-1; SMA: Smooth muscle actin.

Article Snippet: Primary antibodies against collagen 1 (1:2500, catalog No. 67288-1-Ig, Proteintech), α-smooth muscle actin (SMA) (1:200, catalog No. ab5694, Abcam), desmin (1:4000, catalog No. 16520-1-AP, Proteintech), lymphatic vessel endothelial hyaluronan receptor 1 (LyVE-1) (1:100, catalog No. ab219556, Abcam), cluster of differentiation (CD) 34 (1:1000, catalog No. 14486-1-AP, Proteintech), von Willebrand factor (vWF) (1:200, catalog No. 27186-1-AP, Proteintech), vascular endothelial growth factor receptor 2 (VEGFR2) (1:150, catalog No. ab2349, Abcam), vascular endothelial growth factor A (VEGF-A) (1:100, catalog No. ab52917, Abcam), and CD31 (1:5000, catalog No. 11265-1-AP, Proteintech) were applied overnight at 4 °C, followed by 60-minute incubation with secondary antibodies at room temperature.

Techniques: Staining, Immunohistochemistry, Ligation

Journal: Eye and Vision

Article Title: Sexual dimorphism in keratoconus: transcriptomic and hormonal mechanisms underlying stromal remodelling

doi: 10.1186/s40662-026-00478-0

Figure Lengend Snippet: Collagen and α-SMA expression in HCSFs after testosterone stimulation. a , b Western blot showing type I/III collagen and α-SMA expression in HCSFs after testosterone stimulation (50, 100, or 200 pmol/mL; n = 5 per group). c , d Immunofluorescence staining showing protein-expression levels in HCSFs after treatment with 50 pmol/mL testosterone (n = 5 per group). e , f Western blot analysis and quantification of protein-expression levels in HCSFs after treatment with 50 pmol/mL testosterone and 10 μmol/mL flutamide (2 h, 4 h, and 6 h; n = 5 per group). Baseline expression levels in untreated cells are shown in panels ( a ) and ( b ) f(0 pmol/mL testosterone). g , h Immunofluorescence staining and quantification showing protein-expression levels in HCSFs after treatment with 50 pmol/mL testosterone and 10 μmol/mL flutamide (2 h, 4 h, and 6 h; n = 5 per group). Col, collagen; HCSF, human corneal stromal fibroblast; SMA, smooth muscle actin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; DAPI, 4′,6-diamidino-2-phenylindole; MFI, mean fluorescence intensity; * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001

Article Snippet: Antibodies against type I collagen (14695-1-AP, Proteintech), type III collagen (22734-1-AP, Proteintech), and α-SMA (14395-1-AP, Proteintech) were used as primary antibodies, and anti-rabbit IgG (Alexa Fluor 594, Invitrogen) was used as a secondary antibody.

Techniques: Expressing, Western Blot, Immunofluorescence, Staining, Fluorescence

Journal: Eye and Vision

Article Title: Sexual dimorphism in keratoconus: transcriptomic and hormonal mechanisms underlying stromal remodelling

doi: 10.1186/s40662-026-00478-0

Figure Lengend Snippet: Collagen and α-SMA expression in HCSFs treated with fulvestrant and β-oestradiol. a , b Western blot analysis and quantification showing type I/III collagen and α-SMA expression in HCSFs after fulvestrant treatment (0.1, 1, and 10 μmol/mL; n = 5 per group). c , d Immunofluorescence staining and quantification showing protein-expression levels in HCSFs after 1 μmol/mL fulvestrant treatment (n = 5 per group). e , f Western blot analysis and quantification showing protein-expression levels in HCSFs after treatment with 1 μmol/mL fulvestrant and 2 pmol/mL β-oestradiol (2 h, 4 h, and 6 h; n = 5 per group). g , h Immunofluorescence staining and quantification showing protein-expression levels in HCSFs after treatment with 1 μmol/mL fulvestrant and 2 pmol/mL β-oestradiol (2 h, 4 h, and 6 h; n = 5 per group). Col, collagen; HCSF, human corneal stromal fibroblast; SMA, smooth muscle actin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; DAPI, 4′,6-diamidino-2-phenylindole; MFI, mean fluorescence intensity; * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001

Article Snippet: Antibodies against type I collagen (14695-1-AP, Proteintech), type III collagen (22734-1-AP, Proteintech), and α-SMA (14395-1-AP, Proteintech) were used as primary antibodies, and anti-rabbit IgG (Alexa Fluor 594, Invitrogen) was used as a secondary antibody.

Techniques: Expressing, Western Blot, Immunofluorescence, Staining, Fluorescence